Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05089903
Other study ID # UPCC 15121
Secondary ID 849863
Status Completed
Phase N/A
First received
Last updated
Start date October 25, 2021
Est. completion date April 25, 2022

Study information

Verified date June 2022
Source Abramson Cancer Center of the University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This project aims to evaluate different approaches to increase breast cancer screening among primary care patients at Penn Medicine through a centralized screening outreach program. In a pragmatic trial, the investigators will evaluate different approaches to increase completion of screening among eligible patients, including ordering mammograms in bulk prior to outreach, sending personalized text reminders, and endorsing of the communication by the primary care provider.


Description:

While mammograms are recommended by guidelines for early detection of breast cancer, mammogram rates are significantly lower now than they were prior to the initial COVID-19 pandemic surge in early 2020. In this project, the investigators will evaluate different ways of reaching out to eligible patients to encourage them to participate in breast cancer screening. Through letters, texting, and the electronic health record portal (MyPennMedicine (MPM)), the investigators will compare mammogram bulk orders, text messaging, and primary care provider endorsement to traditional outreach messaging with the goal of increasing breast cancer screening uptake.


Recruitment information / eligibility

Status Completed
Enrollment 24680
Est. completion date April 25, 2022
Est. primary completion date January 25, 2022
Accepts healthy volunteers No
Gender Female
Age group 40 Years to 74 Years
Eligibility Inclusion Criteria: 1. Women ages 40-74 2. Followed by Primary Care with a Penn Medicine PCP listed and at least one visit in the last 2 years 3. Health Maintenance due (default biannual screening starting at age 50 or edit modifier based on input by clinician) Exclusion Criteria: 1. Currently scheduled for a mammogram 2. History of bilateral mastectomy

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Bulk Order
A mammogram order will be placed using bulk order technology in the EHR in advance of outreach for all patients.
Texting
In addition to outreach, patients will receive text messaging with information regarding the importance of screening, how to schedule a mammogram, and locations available for mammography.
Clinician Endorsement
Outreach informing patients that they are overdue for a mammogram will be signed by the patient's primary care provider.
No Bulk Order
The outreach will ask patients to contact their PCP's office in order to have a mammogram order placed on their behalf.
Standard Endorsement
Patient's will receive outreach from the practice informing them that they are overdue for a mammogram.

Locations

Country Name City State
United States Penn Medicine Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Abramson Cancer Center of the University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Mammogram Positivity Rate Percent of mammograms that have positive results 3 months
Other Mammogram Completion by Age Groups Percent of patients that complete a mammogram by age groups 3 months
Other Mammogram Completion by Race/Ethnicity Percent of patients that complete a mammogram by race/ethnicity 3 months
Other Mammogram Completion by Insurance Type Percent of patients that complete a mammogram by insurance type 3 months
Other Mammogram Completion by Median Household Income by Zip Code Percent of patients that complete a mammogram by Median Household Income by zip code 3 months
Other Positive Mammograms Resulting in Subsequent Care Percent of patients with a positive mammogram that receive subsequent care 3 months
Other Mammogram Completion by Electronic Patient Portal Status Percent of patients that complete a mammogram by electronic patient portal status 3 months
Primary Mammogram Completion in 3 months Percent of patients that complete a mammogram 3 months
Secondary Mammogram Completion in 6 months Percent of patients that complete a mammogram 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A